Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.

Clinical Trial Description

Neutrophilic dermatoses are a spectrum of inflammatory disorders characterized by skin lesions resulting from a neutrophil-rich inflammatory infiltrate in the absence of infection. Pyoderma gangrenosum is associated with a neutrophilic leukocytosis, which is likely to be triggered by C5a. This study is set up based on the hypothesis that vilobelimab might be able to block C5a induced pro-inflammatory effects such as neutrophil activation and cytokine generation, potentially contributing to the local skin inflammation and tissue damage. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03971643
Study type	Interventional
Source	InflaRx GmbH
Contact
Status	Completed
Phase	Phase 2
Start date	May 16, 2019
Completion date	January 3, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06092216` - Spesolimab in Pyoderma Gangrenosum	Phase 2
Completed	`NCT03311464` - A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan	Phase 3
Recruiting	`NCT04901325` - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Phase 2
Completed	`NCT00791557` - Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease	N/A
Terminated	`NCT02318914` - A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum	Phase 3
Terminated	`NCT02315417` - An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Phase 3
Completed	`NCT03137160` - An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	Phase 2
Not yet recruiting	`NCT05984654` - Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum	N/A
Completed	`NCT04895566` - Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma	Early Phase 1
Withdrawn	`NCT04274166` - Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Phase 2
Completed	`NCT01882504` - Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum	Phase 2
Withdrawn	`NCT00730717` - Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum	Phase 2
Not yet recruiting	`NCT04792957` - JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Not yet recruiting	`NCT05821374` - Deucravacitinib in PG	Early Phase 1
Terminated	`NCT03072953` - Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum	Phase 2
Recruiting	`NCT05120726` - A Novel Therapeutic Treatment of Pyoderma Gangrenosum	Phase 4
Withdrawn	`NCT00690846` - Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	Phase 2
Completed	`NCT01965613` - A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum	Phase 2
Recruiting	`NCT01952275` - Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases	N/A
Completed	`NCT01302795` - Canakinumab for Pyoderma Gangrenosum	Phase 2